ERBB2 and breast cancer: Extensive screening of genomic aberrations has led to the identification of candidate biomarkers associated with breast cancer tumorigenesis, invasiveness, and metastasis, including MYC at 8q24 [67], CCND1 at 11q13 [68], Her-2 at 17q12 [53], MTDH at 8q22 [69,70], and ETS transcription factors at 1q21 and 1q32 [71].